Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BGM BGM Group	$7.82 +3.9%	$9.93	$5.47 ▼ $17.17	$759.77M	1.26	48,084 shs	4,356 shs
NAGE Niagen Bioscience	$9.98 +2.1%	$11.25	$3.10 ▼ $14.69	$795.94M	2.12	942,136 shs	508,795 shs
NLTX Neoleukin Therapeutics	$19.75 +0.7%	$20.31	$2.03 ▼ $14.36	$185.61M	1.11	50,104 shs	51,034 shs
NRIX Nurix Therapeutics	$10.10 +4.6%	$11.44	$8.18 ▼ $29.56	$773.29M	2.14	864,186 shs	403,485 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BGM BGM Group	-4.69%	-0.66%	-25.10%	-48.70%	+28.55%
NAGE Niagen Bioscience	+1.45%	+0.62%	+3.39%	-1.11%	+192.51%
NLTX Neoleukin Therapeutics	0.00%	-6.63%	-11.77%	+9.26%	-45.01%
NRIX Nurix Therapeutics	+1.26%	-8.62%	-14.22%	-0.72%	-59.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BGM BGM Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NAGE Niagen Bioscience	1.3419 of 5 stars	3.5	0.0	0.0	0.0	1.7	0.0	0.0
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	2.3985 of 5 stars	4.4	2.0	0.0	0.0	1.4	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BGM BGM Group	0.00	N/A	N/A	N/A
NAGE Niagen Bioscience	3.00	Buy	$13.42	34.47% Upside
NLTX Neoleukin Therapeutics	0.00	N/A	N/A	N/A
NRIX Nurix Therapeutics	2.81	Moderate Buy	$28.87	185.95% Upside

Current Analyst Ratings Breakdown

Latest NLTX, NAGE, BGM, and NRIX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	NAGE Niagen Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $12.00
7/31/2025	NRIX Nurix Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$32.00 ➝ $30.00
7/15/2025	NRIX Nurix Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$17.00 ➝ $16.00
7/14/2025	NRIX Nurix Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $34.00
7/10/2025	NRIX Nurix Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $26.00
7/10/2025	NRIX Nurix Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
7/10/2025	NRIX Nurix Therapeutics	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$30.00
6/10/2025	NAGE Niagen Bioscience	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $16.00
6/6/2025	NAGE Niagen Bioscience	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $23.00
5/27/2025	NAGE Niagen Bioscience	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$13.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BGM BGM Group	$25.10M	30.27	N/A	N/A	$7.34 per share	1.06
NAGE Niagen Bioscience	$116.30M	6.84	$0.06 per share	162.81	$0.80 per share	12.48
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	$11.08 per share	N/A
NRIX Nurix Therapeutics	$54.55M	14.15	N/A	N/A	$7.44 per share	1.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BGM BGM Group	-$1.44M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
NAGE Niagen Bioscience	$8.55M	$0.21	47.53	∞	N/A	15.24%	23.12%	15.53%	N/A
NLTX Neoleukin Therapeutics	-$57.56M	-$3.11	N/A	∞	N/A	N/A	-37.22%	-30.91%	N/A
NRIX Nurix Therapeutics	-$193.57M	-$2.61	N/A	N/A	N/A	-234.57%	-45.26%	-34.71%	10/10/2025 (Estimated)

Latest NLTX, NAGE, BGM, and NRIX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2025	Q2 2025	NAGE Niagen Bioscience	$0.02	$0.04	+$0.02	$0.04	$28.55 million	$31.12 million
7/9/2025	Q2 2025	NRIX Nurix Therapeutics	-$0.79	-$0.52	+$0.27	-$0.52	$16.26 million	$44,056.00 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BGM BGM Group	N/A	N/A	N/A	N/A	N/A
NAGE Niagen Bioscience	N/A	N/A	N/A	N/A	N/A
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BGM BGM Group	N/A	1.82	1.45
NAGE Niagen Bioscience	N/A	3.88	3.24
NLTX Neoleukin Therapeutics	N/A	15.33	15.33
NRIX Nurix Therapeutics	N/A	6.82	6.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BGM BGM Group	N/A
NAGE Niagen Bioscience	15.41%
NLTX Neoleukin Therapeutics	52.37%
NRIX Nurix Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
BGM BGM Group	58.66%
NAGE Niagen Bioscience	9.39%
NLTX Neoleukin Therapeutics	1.58%
NRIX Nurix Therapeutics	7.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BGM BGM Group	298	97.22 million	40.19 million	N/A
NAGE Niagen Bioscience	120	79.75 million	72.26 million	N/A
NLTX Neoleukin Therapeutics	90	9.40 million	9.25 million	No Data
NRIX Nurix Therapeutics	300	76.45 million	70.79 million	Optionable

NLTX, NAGE, BGM, and NRIX Headlines

Recent News About These Companies

Nurix Therapeutics (NASDAQ:NRIX) Trading Down 4.4% - Time to Sell?

August 20 at 5:14 PM | marketbeat.com

Deutsche Bank AG Has $4.52 Million Position in Nurix Therapeutics, Inc. $NRIX

August 19 at 4:01 AM | marketbeat.com

Nurix Therapeutics (NASDAQ:NRIX) Trading Up 7.7% - Should You Buy?

August 15, 2025 | marketbeat.com

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by Victory Capital Management Inc.

August 3, 2025 | marketbeat.com

Houte Hans Van Sells 5,402 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock

August 2, 2025 | marketbeat.com

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van Sells 5,402 Shares

August 2, 2025 | insidertrades.com

Oppenheimer Reiterates "Outperform" Rating for Nurix Therapeutics (NASDAQ:NRIX)

August 1, 2025 | marketbeat.com

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Sells $51,691.04 in Stock

July 31, 2025 | marketbeat.com

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Gwenn Hansen Sells 4,308 Shares

July 31, 2025 | marketbeat.com

6NRIX : 6 Analysts Assess Nurix Therapeutics: What You Need To Know

July 31, 2025 | benzinga.com

Houte Hans Van Sells 4,304 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock

July 31, 2025 | insidertrades.com

Nurix Therapeutics (NASDAQ:NRIX) Shares Up 4.9% - Here's What Happened

July 29, 2025 | marketbeat.com

Y Intercept Hong Kong Ltd Invests $374,000 in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

July 29, 2025 | marketbeat.com

ARK Investment Management LLC Has $18.90 Million Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

July 27, 2025 | marketbeat.com

Nikko Asset Management Americas Inc. Decreases Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

July 27, 2025 | marketbeat.com

New York State Common Retirement Fund Has $626,000 Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

July 26, 2025 | marketbeat.com

Massachusetts Financial Services Co. MA Sells 24,398 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

July 22, 2025 | marketbeat.com

Nurix Therapeutics price target lowered to $34 from $36 at H.C. Wainwright

July 15, 2025 | finance.yahoo.com

Nurix Therapeutics Could Disrupt BTK Therapy And Reward Investors

July 13, 2025 | seekingalpha.com

Nurix Therapeutics beats quarterly expectations on strong collaboration ...

July 11, 2025 | investing.com

Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

July 10, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NLTX, NAGE, BGM, and NRIX Company Descriptions

BGM Group NASDAQ:BGM

$7.82 +0.30 (+3.92%)

As of 03:44 PM Eastern

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Niagen Bioscience NASDAQ:NAGE

$9.98 +0.21 (+2.15%)

As of 03:28 PM Eastern

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Neoleukin Therapeutics NASDAQ:NLTX

$19.75 +0.14 (+0.71%)

As of 08/21/2025

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Nurix Therapeutics NASDAQ:NRIX

$10.10 +0.45 (+4.61%)

As of 03:45 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time